Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Healthstream (HSTM) Cash & Equivalents (2016 - 2026)

Healthstream has reported Cash & Equivalents over the past 16 years, most recently at $36.2 million for Q4 2025.

  • Quarterly Cash & Equivalents fell 39.19% to $36.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $36.2 million through Dec 2025, down 39.19% year-over-year, with the annual reading at $36.2 million for FY2025, 39.19% down from the prior year.
  • Cash & Equivalents was $36.2 million for Q4 2025 at Healthstream, down from $53.5 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $77.3 million in Q1 2025 and troughed at $25.8 million in Q2 2023.
  • The 5-year median for Cash & Equivalents is $47.6 million (2021), against an average of $48.3 million.
  • Year-over-year, Cash & Equivalents plummeted 57.79% in 2021 and then surged 78.77% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $46.9 million in 2021, then dropped by 1.88% to $46.0 million in 2022, then decreased by 12.36% to $40.3 million in 2023, then surged by 47.45% to $59.5 million in 2024, then plummeted by 39.19% to $36.2 million in 2025.
  • Per Business Quant, the three most recent readings for HSTM's Cash & Equivalents are $36.2 million (Q4 2025), $53.5 million (Q3 2025), and $52.1 million (Q2 2025).